JNJ-26854165 (Serdemetan)

Catalog No.S1172

Molecular Weight(MW): 328.41

JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.

Cited by 4 Publications

Mol Ther, 2015, 23(5):857-65

PubMed: 25648263

BMC Pharmacol Toxicol, 2017, 18(1):40

PubMed: 28577368

Sci Rep, 2014, 4:4664

PubMed: 24722541

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420

6 Customer Reviews

Mol Pharmacol 2014 85(3), 408-19. JNJ-26854165 (Serdemetan) purchased from Selleck.

J Nat Med 2013 10.1007/s11418-014-0825-0. JNJ-26854165 (Serdemetan) purchased from Selleck.
Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.
Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

Curr Protoc Chem Biol 2013 5(3), 195-212. JNJ-26854165 (Serdemetan) purchased from Selleck.

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Description

Targets

p53 ^[1]
(Cell-free assay)

HDM2 ^[1]
(Cell-free assay)

Mdm2 ^[2]
(Cell-free assay)

In vitro

JNJ 26854165 is a novel tryptamine derivative which activates p53 and acts as a HDM2 ubiquitin ligase antagonist. JNJ 26854165 inhibits cell growth and induces apoptosis in leukemia cell lines with IC50 values of 0.24, 0.33, 0.32 and 0.44 μM at 72 hours for OCI-AML-3, MOLM-13, NALM-6 and REH cells, respectively. In addition, JNJ 26854165 accelerates proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53. It also induces S-phase delay and upregulates E2F1 expression in p53 mutant cells, resulting in preferential apoptosis of S-phase cells. ^[1] JNJ 26854165 is an oral Mdm2 inhibitor which can inhibit the interaction of Mdm2-p53 complex with the proteasome and increase p53 levels by binding to RING domain of Mdm2. ^[2] A recent study shows that JNJ 26854165 inhibits clonogenic survival in four human cancer cell lines: H460, A549, p53-WT-HCT116, and p53-null-HCT116. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KU-19-19 cell	NYnJeG1{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NEXJdJZKdmirYnn0bY9vKG:oIHj1cYFvKEuXLUG5MVE6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC57M{KzOkDPxE1?	MUfTRW5ITVJ?
H4 cell	M{\SVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M{\vT2lvcGmkaYTpc44hd2ZiaIXtZY4hUDRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkC2O\|A4KM7:TR?=	NFnGXnNUSU6JRWK=
KGN cell	Mn7HS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M2ryeWlvcGmkaYTpc44hd2ZiaIXtZY4hU0eQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT62NlA2KM7:TR?=	Ml7VV2FPT0WU
786-0 cell	M2Hwbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M1exRmlvcGmkaYTpc44hd2ZiaIXtZY4hPzh4LUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlczQTh7IN88US=>	MWLTRW5ITVJ?
769-P cell	NULGPHNFT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MlvETY5pcWKrdHnvckBw\iCqdX3hckA4PjlvUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuPFIzOjRizszN	MVPTRW5ITVJ?
K5 cell	MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M3m3dmlvcGmkaYTpc44hd2ZiaIXtZY4hUzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkCxOlI1KM7:TR?=	NV3PfphHW0GQR1XS
MLMA cell	NI\XPHlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M3;G[WlvcGmkaYTpc44hd2ZiaIXtZY4hU0:VQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4xOzJzNzFOwG0>	MVfTRW5ITVJ?
MLMA cell	M4jBXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NGnZR5ZKdmirYnn0bY9vKG:oIHj1cYFvKE2OTVGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlI5PzB\|IN88US=>	MonyV2FPT0WU
EW-7 cell	NGXUcmlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MXzJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkOyOlk2KM7:TR?=	MVHTRW5ITVJ?
SW1088 cell	MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NWS4dmVsUW6qaXLpeIlwdiCxZjDoeY1idiCVV{GwPFgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjhyNkWxJO69VQ>?	M4jvSHNCVkeHUh?=
MC-IXC cell	NGHMT4RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MlXJTY5pcWKrdHnvckBw\iCqdX3hckBOSy2LWFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlg4Pzl{IN88US=>	MmXqV2FPT0WU
NCI-H2052 cell	NFr6bHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M2T0b2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNFUzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5yOEG1O{DPxE1?	MnL1V2FPT0WU
IGR-1 cell	NW\5TZFlT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M3fVO2lvcGmkaYTpc44hd2ZiaIXtZY4hUUeULUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlEzODJ6IN88US=>	MYLTRW5ITVJ?
DSH1 cell	Ml\qS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MWPJcohq[mm2aX;uJI9nKGi3bXHuJGRUUDFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1\|LkK0Nlk3KM7:TR?=	MnztV2FPT0WU
PA-1 cell	NVP6SJJJT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M37heWlvcGmkaYTpc44hd2ZiaIXtZY4hWEFvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuN\|AxPToQvF2=	M3O1RXNCVkeHUh?=
SK-MEL-3 cell	Mn73S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M37BXmlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjNzMkC3JO69VQ>?	MlP6V2FPT0WU
SW900 cell	M1jvSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3;WXWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7MECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlQ5OjV3IN88US=>	NHSxeHBUSU6JRWK=
CAKI-1 cell	M4H4[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MYXJcohq[mm2aX;uJI9nKGi3bXHuJGNCU0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuOVI4OzhizszN	MoK4V2FPT0WU
ES1 cell	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MWDJcohq[mm2aX;uJI9nKGi3bXHuJGVUOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTNwNUK4PVch\|ryP	MVvTRW5ITVJ?
SK-N-DZ cell	NYPENWYzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NFrySFVKdmirYnn0bY9vKG:oIHj1cYFvKFONLV6tSHoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ{NUm1JO69VQ>?	MWLTRW5ITVJ?
RH-1 cell	M2r0cWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NFn5eYJKdmirYnn0bY9vKG:oIHj1cYFvKFKKLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlY5PDZ\|IN88US=>	NFL3OGFUSU6JRWK=
ES8 cell	MnmxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NHjEUHZKdmirYnn0bY9vKG:oIHj1cYFvKEWVODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuOlk4ODJizszN	MlO0V2FPT0WU
NEC8 cell	Mlv1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MYnJcohq[mm2aX;uJI9nKGi3bXHuJG5GSzhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1\|Lke2PVgzKM7:TR?=	NEPi[\|ZUSU6JRWK=
LNCaP-Clone-FGC cell	MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVXJcohq[mm2aX;uJI9nKGi3bXHuJGxPS2GSLVPsc45mNU[JQzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuPFM2OzZizszN	MnTqV2FPT0WU
HCE-4 cell	NYjoNmpYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NFryNlRKdmirYnn0bY9vKG:oIHj1cYFvKEiFRT20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{46QDB5IN88US=>	MWLTRW5ITVJ?
U-118-MG cell	MoTwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NFjaUXhKdmirYnn0bY9vKG:oIHj1cYFvKFVvMUG4MW1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5yMUC2OkDPxE1?	MmrLV2FPT0WU
GI-ME-N cell	NYPuO2tHT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M2DTbGlvcGmkaYTpc44hd2ZiaIXtZY4hT0lvTVWtUkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvODh5OU[g{txO	M3nmXXNCVkeHUh?=
LB1047-RCC cell	NIq0VpVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M2qwemlvcGmkaYTpc44hd2ZiaIXtZY4hVEJzMES3MXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTRwMU[xOFMh\|ryP	NXjjUVBqW0GQR1XS
HT-1080 cell	M2Doemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M1f0O2lvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOTl7MkGg{txO	MmXTV2FPT0WU
NB69 cell	MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NXKwTGdpUW6qaXLpeIlwdiCxZjDoeY1idiCQQk[5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4{PTB2NzFOwG0>	M3uxSHNCVkeHUh?=
NCI-H1693 cell	Mm\sS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M3rnV2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOlk{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC52NEi5OUDPxE1?	MkP1V2FPT0WU
HSC-3 cell	M3PjZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M4DNfmlvcGmkaYTpc44hd2ZiaIXtZY4hUFOFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlQ6QTN\|IN88US=>	MWfTRW5ITVJ?
MDA-MB-231 cell	NITTXoNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MVrJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjV3OEm5JO69VQ>?	NHrQVYZUSU6JRWK=
HOS cell	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NYjlU3BqUW6qaXLpeIlwdiCxZjDoeY1idiCKT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc5PjNizszN	M{XmZ3NCVkeHUh?=
BT-549 cell	NVnKVFd4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MnTUTY5pcWKrdHnvckBw\iCqdX3hckBDXC13NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc5QDdizszN	NV\3XYdTW0GQR1XS
NB17 cell	NVXiWYdGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MX3Jcohq[mm2aX;uJI9nKGi3bXHuJG5DOTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Lke4PVc3KM7:TR?=	M4XCWnNCVkeHUh?=
5637 cell	NHrmS2ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MmnJTY5pcWKrdHnvckBw\iCqdX3hckA2PjN5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND63PVY2OiEQvF2=	MYXTRW5ITVJ?
OVCAR-8 cell	MkHyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NVjkeFlIUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk05KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC57MkSzOkDPxE1?	MUPTRW5ITVJ?
G-402 cell	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NWO4SWpwUW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTNyM{Wg{txO	MmHSV2FPT0WU
BB30-HNC cell	NXHQOVB{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MWnJcohq[mm2aX;uJI9nKGi3bXHuJGJDOzBvSF7DJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4xPzJzODFOwG0>	M1O3bnNCVkeHUh?=
HCC1806 cell	MlSyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NYXHRVJVUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxPFA3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5yOEOzPUDPxE1?	MmLRV2FPT0WU
COLO-800 cell	NF\3ZWVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NGXrTlhKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tPFAxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5zMk[0JO69VQ>?	NX;YbJVFW0GQR1XS
FADU cell	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M1Lwd2lvcGmkaYTpc44hd2ZiaIXtZY4hTkGGVTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuN\|Y2PTdizszN	M2P4VnNCVkeHUh?=
NCI-H1651 cell	NFnHbJhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NWmwe2pPUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE3PTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkO5OFA6KM7:TR?=	MUHTRW5ITVJ?
AGS cell	NIP5OY9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NIiyfWVKdmirYnn0bY9vKG:oIHj1cYFvKEGJUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuOFc4OTFizszN	MXfTRW5ITVJ?
CHP-212 cell	M2D3WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NETodGJKdmirYnn0bY9vKG:oIHj1cYFvKEOKUD2yNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjN7NEC5JO69VQ>?	NUHJfmpIW0GQR1XS
YAPC cell	M4T2UGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NEf6bHhKdmirYnn0bY9vKG:oIHj1cYFvKFmDUFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ4PzFzIN88US=>	MXzTRW5ITVJ?
GOTO cell	NI\6RpVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MWLJcohq[mm2aX;uJI9nKGi3bXHuJGdQXE9iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkS5OVc3KM7:TR?=	NEHuWGFUSU6JRWK=
KYSE-510 cell	MkXhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MkfVTY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUWxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPTFzIN88US=>	M1nlO3NCVkeHUh?=
NCI-H2342 cell	NV\DfnVHT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Mn3PTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKzOFIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjV\|Mke4JO69VQ>?	NETUXWdUSU6JRWK=
BFTC-905 cell	MnTRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MWHJcohq[mm2aX;uJI9nKGi3bXHuJGJHXENvOUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU43Ojh\|NTFOwG0>	M2XadXNCVkeHUh?=
EW-16 cell	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MkGyTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuO\|IxQTNizszN	MkXiV2FPT0WU
SK-MEL-30 cell	MmPpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MkHCTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytN\|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Njd2NUSzJO69VQ>?	NYnVdJR7W0GQR1XS
HLE cell	M4mybWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MWLJcohq[mm2aX;uJI9nKGi3bXHuJGhNTSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwN{e0PFkh\|ryP	NEL6c4tUSU6JRWK=
T98G cell	M2m2VWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NX7xUZJ5UW6qaXLpeIlwdiCxZjDoeY1idiCWOUjHJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU44QTZ\|NTFOwG0>	NYDvSo9[W0GQR1XS
HUTU-80 cell	NV7hZnNbT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MWXJcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlg1OjJ6IN88US=>	NVO3WnRDW0GQR1XS
NOS-1 cell	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NUDMZ4oxUW6qaXLpeIlwdiCxZjDoeY1idiCQT2OtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTR5Nk[g{txO	NFXUbHlUSU6JRWK=
SW780 cell	Ml7TS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NVHZelRiUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTZ7NEmg{txO	Mk\NV2FPT0WU
KYSE-180 cell	MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NVHjTZNlUW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVE5OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwOUe2OVQh\|ryP	NGT4bGNUSU6JRWK=
MDA-MB-361 cell	NEntb21Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NVXtfnZ3UW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT65PFY1PyEQvF2=	MmHVV2FPT0WU
SNU-C2B cell	MonIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NXfNZ4JoUW6qaXLpeIlwdiCxZjDoeY1idiCVTmWtR\|JDKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5yMUGzPEDPxE1?	MmXNV2FPT0WU
NCI-H661 cell	NF;FOppIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M3zaOGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi2OlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjB4OUSg{txO	M3:yUHNCVkeHUh?=
OE33 cell	NYHseJhrT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NGjRbGdKdmirYnn0bY9vKG:oIHj1cYFvKE:HM{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlE1Ozh7IN88US=>	NFj0fnRUSU6JRWK=
TYK-nu cell	NXfnSIRVT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NUX1eXJFUW6qaXLpeIlwdiCxZjDoeY1idiCWWVutcpUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjJzOE[zJO69VQ>?	M{fhOHNCVkeHUh?=
COLO-792 cell	NE\pXFJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NILuOIlKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tO\|kzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5{NUKxPUDPxE1?	MX\TRW5ITVJ?
HEL cell	M1HTU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NVr5bFlnUW6qaXLpeIlwdiCxZjDoeY1idiCKRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlI3PzZizszN	NFXNW3RUSU6JRWK=
D-566MG cell	NVu0SWM2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MmraTY5pcWKrdHnvckBw\iCqdX3hckBFNTV4Nl3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4{OzR7MTFOwG0>	MWnTRW5ITVJ?
U031 cell	NX;YXI5OT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M3nB[2lvcGmkaYTpc44hd2ZiaIXtZY4hXTB\|MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[uOFE5OTZizszN	M4HYXXNCVkeHUh?=
COR-L23 cell	M3rwcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NYi5UIdrUW6qaXLpeIlwdiCxZjDoeY1idiCFT2KtUFI{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi52M{O0OkDPxE1?	M4TleHNCVkeHUh?=
NCI-H2452 cell	NGPxfo1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	Mk\YTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEK0OVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjV{MkixJO69VQ>?	NITOT\|ZUSU6JRWK=
BB65-RCC cell	M1rx[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3f2cGlvcGmkaYTpc44hd2ZiaIXtZY4hSkJ4NT3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjZ2NUmg{txO	NF;VU\|RUSU6JRWK=
CAL-33 cell	NHLzfXRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NF7QOpFKdmirYnn0bY9vKG:oIHj1cYFvKEODTD2zN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPjV4NkWg{txO	NIr6b4VUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo

JNJ 26854165 leads to significant differences in EFS distribution in 17 of the 36 (47%) evaluable solid tumor xenografts and in 5 of 7 (71%) of the evaluable ALL xenografts using a dose of 20 mg/kg administered via oral gavage daily for 5 days, repeated for 6 weeks. ^[4]

Protocol

Cell Research:^[1]	+ Expand Cell lines: OCI-AML-3, MOLM-13, NB4 and U937 cells Concentrations: 0-10 μM Incubation Time: 72 hours Method: Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK (Only for Reference)
Animal Research:^[4]	+ Expand Animal Models: CB17SC scid^-/- female mice. Formulation: JNJ-26854165 is dissolved in DMSO and then diluted in water. Dosages: ≤20 mg/kg Administration: Administered via p.o. (Only for Reference)

Cell Research:^[1]

+ Expand

Cell lines: OCI-AML-3, MOLM-13, NB4 and U937 cells
Concentrations: 0-10 μM
Incubation Time: 72 hours
Method: Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK
(Only for Reference)

Animal Research:^[4]

+ Expand

Animal Models: CB17SC scid^-/- female mice.
Formulation: JNJ-26854165 is dissolved in DMSO and then diluted in water.
Dosages: ≤20 mg/kg
Administration: Administered via p.o.
(Only for Reference)

References

[4] Smith MA, et al. Pediatr Blood Cancer, 2012, 59(2), 329-332.

+ Expand

Solubility (25°C)

In vitro	DMSO	66 mg/mL (200.96 mM)
	Ethanol	2 mg/mL (6.08 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% DMSO+30% polyethylene glycol+1% Tween 80 For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download JNJ-26854165 (Serdemetan) SDF

Molecular Weight	328.41
Formula	C₂₁H₂₀N₄
CAS No.	881202-45-5
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-15)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00676910	Completed	Neoplasms	Johnson & Johnson Pharmaceutical Research & Development L.L.C.	November 2006	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

p53 Signaling Pathway Map

Related p53 Products0

MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
RITA (NSC 652287)

RITA (NSC 652287) induces both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks, and also inhibits MDM2-p53 interaction by targeting p53.

Features:Inducer of DNA cross-links, not a DNA intercalator.
Pifithrin-α (PFTα) HBr

Pifithrin-α is an inhibitor of p53, inhibiting p53-dependent transactivation of p53-responsive genes.
Tenovin-1

Tenovin-1 protects against MDM2-mediated p53 degradation, which involves ubiquitination, and acts through inhibition of protein-deacetylating activities of SirT1 and SirT2.
Tenovin-6

Tenovin-6 is a small molecule activator of p53 transcriptional activity.
NSC 319726

NSC319726 is a p53(R175) mutant reactivator, exhibits growth inhibition in cells expressing mutant p53, with IC50 of 8 nM for p53(R175) mutant, shows no inhibition for p53 wild-type cells.

Features:An allele-specific p53 mutant reactivator.
Pifithrin-μ

Pifithrin-μ is a specific p53 inhibitor by reducing its affinity to Bcl-xL and Bcl-2, and also inhibits HSP70 function and autophagy.
Z-VAD-FMK

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Features:A key compound for apoptosis studies.

Choose Your Country or Region

By Signaling Pathways

By product type

JNJ-26854165 (Serdemetan)

Cited by 4 Publications

6 Customer Reviews

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download JNJ-26854165 (Serdemetan) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-15)

Tech Support

p53 Signaling Pathway Map

Related p53 Products0

Choose Your Country or Region

By Signaling Pathways

By product type

JNJ-26854165 (Serdemetan)

Cited by 4 Publications

6 Customer Reviews

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download JNJ-26854165 (Serdemetan) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-15)

Tech Support

p53 Signaling Pathway Map

Related p53 Products0

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)